Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MenABCWY Vaccine in MenACWY-Primed Adolescents and Adults
NCT04707391Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2021
- Primary completion
- May 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 3 trial of pexidartinib in meningococcal meningitis, sponsored by GSK. Started Jan 2021; status: completed.
02
Drugs
pexidartinib
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT04707391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04707391.